IPCA Laboratories IPCA.NS IPCA IN EQUITY: HEALTH CARE & PHARMACEUTICALS Beat and raise in 1QFY27 All segments deliver double-digit growth; management lifts revenue and margin targets for FY27E; maintain Buy 1QFY27: Robust start to the year; management raises FY27E guidance IPCA delivered a robust start to FY27, with sales/EBITDA/PAT growing 21%/50%/72% y-y in 1QFY27 ( Fig. 1 ) . All business and geography segments recorded double-digit y-y growth. API and export performance were significantly strong during ...